Opus Genetics, INC. (IRD) — 10-Q Filings

All 10-Q filings from Opus Genetics, INC.. Browse 5 Quarterly Report reports with AI-powered summaries and risk analysis.

10-Q Filings (5)

Opus Genetics' Loss Widens Amid Gene Therapy Push, Warrant Costs — Nov 12, 2025 Risk: high
Opus Genetics, Inc. (IRD) reported a significant increase in net loss for the nine months ended September 30, 2025, reaching $33.068 million, up from $22.397 mi
Opus Genetics Narrows Q2 Loss, Boosted by Viatris Revenue — Aug 13, 2025 Risk: medium
Opus Genetics, Inc. (IRD) reported a net loss of $7.42 million for the three months ended June 30, 2025, a slight improvement from the $7.765 million net loss i
Opus Genetics Files Q1 2025 10-Q — May 15, 2025 Risk: medium
Opus Genetics, Inc. filed its quarterly report for the period ending March 31, 2025. The company, formerly known as Ocuphire Pharma, Inc., is in the pharmaceuti
Opus Genetics Files Q3 2024 10-Q — Nov 12, 2024 Risk: medium
Opus Genetics, Inc. filed its 10-Q for the period ending September 30, 2024. The company, formerly known as Ocuphire Pharma, Inc., reported financial results an
Ocuphire Pharma Files Q2 2024 10-Q — Aug 13, 2024 Risk: medium
Ocuphire Pharma, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported its financial results and provided updates on its business operat

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX